ChemExpress has established High-Throughput Experimentation (HTE) platform to keep up with the increasing demand of pharmaceutical timelines in drug discovery and development. HTE is a powerful tool that allows the execution of large numbers of experiments in parallel while requiring limited material and less effort per-experiment. Taking these advantages, we are able to optimize individual steps in a total synthesis for solving complex chemical problems.

ChemExpress has established an industry-leading continuous manufacturing (flow chemistry) platform offering process development and manufacturing services for projects from pre-clinical to commercialization.

ChemExpress' comprehensive biocatalysis platform provides a one-stop solution for all of your biocatalysis challenges; this includes enzyme screening and fermentation as well as process development and cGMP production.

ChemExpress offers one-stop preparative chromatographic stand-alone services for separation, purification and production of APIs and advanced intermediates under GMP. We are equipped with prep-HPLC and prep-SFC production systems that can support milligram to kilogram scale production.

Our solid-state chemistry research technology platform has served many pharmaceutical companies around the world. It has successfully promoted the process from free form polymorph screening to the scale-up production of commercial ton-scale.

Meanwhile, the Chemexpress platform has close cooperation with well-known pharmaceutical companies concentrating on formulation R&D services, so far, one-stop service has achieved in some varieties from API synthesis process development to commercialization.

Chemexpresss committed to sustainable development, adhering to the concept of green chemistry, photochemistry can offers a green, cost-effective option.

For the active pharmaceutical ingredients (APIs) that fall into BCS (biopharmaceutical classification system) 2 and 4 spaces, advanced formulation approaches are required to enhance their aqueous solubility and bioavailability. Solid amorphous dispersions via spray drying is one of the enabling approaches.

An increasing challenges faced today by the pharmaceutical industry is approximately 40% of currently marketed drugs are classified as poorly soluble (BCS Class II/IV), and more than 70% of drugs in development are also poorly soluble, especially when the molecule has both low solubility and a high dose.

The mechanism of HME is to disperse APIs in the polymer matrix at the molecular level to form amorphous solid dispersions. Amorphous solid dispersions can improve bioavailability in more than 80% of cases. The advantage of HME technology is the capability of continuous manufacturing with solvent-less processing and friendly downstream processing of extrudates into final dosage forms (tablets, capsules, controlled release forms etc). HME is increased use in the pharmaceutical industry.